Raised full-year adjusted EPS guidance to at least $27.00; CEO Gail Boudreaux cited stronger execution, targeted investments, and a goal of at least 12% adjusted EPS growth in 2027.
Q2 FY26 results and segment performance
Elevance Health Q2 2026 shareholders’ net income fell 16.1% to $1.46 billion; diluted EPS dropped 13.1% to $6.71.
Operating revenue rose 0.8% to $49.8 billion; operating gain slid 27.3% to $1.76 billion, cutting operating margin by 1.4 percentage points to 3.5%.
Benefit expense ratio widened 0.8 percentage points to 89.7%; operating expense ratio increased 1 percentage point to 11.1%.
Health Benefits operating gain sank 42.6% to $896 million; Carelon operating revenue climbed 6% to $19.2 billion, with operating gain steady at $900 million.
ELV•
